Double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in college students with ADHD
Document Type
Article
Date of Original Version
4-1-2012
Abstract
Objective: To evaluate stimulant medication on symptoms and functioning for college students with ADHD using doubleblind, placebo-controlled, crossover design. Method: Participants included 24 college students with ADHD and 26 college students without psychopathology. Lisdexamfetamine dimesylate (LDX) was examined for ADHD participants over five weekly phases (no-drug baseline, placebo, 30-, 50-, and 70-mg LDX per day). Self-report rating scales of functioning and direct assessment of ADHD symptoms, verbal learning/memory, and adverse side effects were collected (baseline only for control students). Results: LDX was associated with large reductions in ADHD symptoms and improvement in executive functioning along with smaller effects for psychosocial functioning. Reduction in ADHD symptoms was found for 86.4% of participants; however, large differences in symptoms and executive functioning remained relative to controls. Conclusion: LDX is a safe, efficacious treatment for symptom relief in college students with ADHD. Research documenting medication effects on academic functioning and evaluating psychosocial/educational interventions is needed. © 2012 SAGE Publications.
Publication Title, e.g., Journal
Journal of Attention Disorders
Volume
16
Issue
3
Citation/Publisher Attribution
DuPaul, George J., Lisa L. Weyandt, Joseph S. Rossi, Brigid A. Vilardo, Sean M. O'Dell, Kristen M. Carson, Genevieve Verdi, and Anthony Swentosky. "Double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in college students with ADHD." Journal of Attention Disorders 16, 3 (2012): 202-220. doi: 10.1177/1087054711427299.